Garuda Therapeutics

Garuda Therapeutics is a biotechnology startup founded in 2021, with the slogan "Creating off-the-shelf, long-term durable blood stem cell therapies." The company's mission is to eliminate the reliance on donor or patient cells for blood stem cell transplants. Their platform technology aims to generate off-the-shelf, self-renewing blood stem cells, offering patients rapid and broad access to consistent, durable, HLA-compatible transgene-free blood stem cell therapies. The potential impact is significant, as this technology could provide potentially curative therapies for more than 120 diseases. Garuda Therapeutics is based in the United States. They recently secured a substantial $62.00M Series B investment on 07 February 2023. The round was led by prominent investors including OrbiMed, Aisling Capital, Alexandria Venture Investments, Cormorant Asset Management, Northpond Ventures, Sectoral Asset Management, and Mass General Brigham Ventures. With their innovative approach and strong investor backing, Garuda Therapeutics is poised to make substantial strides in the biotechnology and healthcare industries. Learn more about Garuda Therapeutics at garudatx.com.